REFERENCES
1. Salvador F, Llorente A, Gomis RR. From latency to overt bone metastasis in breast cancer: potential for treatment and prevention. J Pathol 2019;249:6-18.
2. George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C, Ottewell P. Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. J Bone Oncol 2020;25:100317.
3. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
4. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008;10:202-10.
5. Cox TR, Rumney RMH, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015;522:106-10.
6. Tulotta C, Lefley DV, Freeman K, et al. Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clin Cancer Res 2019;25:2769-82.
7. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature 2016;529:298-306.
8. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
9. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse. Breast Cancer Res Treat 2003;78:105-18.
10. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010;10:871-7.
11. Tahara RK, Brewer TM, Theriault RL, Ueno NT. . Bone Metastasis of Breast Cancer. In: Ahmad A, editor. Breast Cancer Metastasis and Drug Resistance. Cham: Springer International Publishing; 2019. pp. 105-29.
12. Owen KL, Parker BS. Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. Mol Immunol 2019;110:57-68.
14. Heilmann T, Rumpf AL, Roscher M, et al. Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model. Arch Gynecol Obstet 2020;301:1493-502.
15. Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007;101:135-48.
16. Eyre R, Alférez DG, Santiago-Gómez A, et al. Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat Commun 2019;10:5016.
17. Tulotta C, Groenewoud A, Snaar-jagalska BE, Ottewell P. . Animal Models of Breast Cancer Bone Metastasis. In: Idris AI, editor. Bone Research Protocols. New York: Springer; 2019. pp. 309-30.
18. Ottewell PD, Deux B, Mönkkönen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14:4658-66.
19. Nutter F, Holen I, Brown HK, et al. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer 2014;21:327-41.
20. Reed ND, Manning DD. Long-term maintenance of normal human skin on congenitally athymic (nude) mice. Proc Soc Exp Biol Med 1973;143:350-3.
21. Zhang X, Lewis MT. Establishment of Patient-Derived Xenograft (PDX) Models of Human Breast Cancer. Curr Protoc Mouse Biol 2013;3:21-9.
22. Kanaya N, Somlo G, Wu J, et al. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers. J Steroid Biochem Mol Biol 2017;170:65-74.
23. Lefley D, Howard F, Arshad F, et al. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Res 2019;21:130.
24. Okada S, Vaeteewoottacharn K, Kariya R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019;8:889.
25. Han Y, Nakayama J, Hayashi Y, et al. Establishment and characterization of highly osteolytic luminal breast cancer cell lines by intracaudal arterial injection. Genes Cells 2020;25:111-23.
26. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002;62:917-23.
27. Isoda T, BaBa S, Maruoka Y, et al. Influence of the Different Primary Cancers and Different Types of Bone Metastasis on the Lesion-based Artificial Neural Network Value Calculated by a Computer-aided Diagnostic System, BONENAVI, on Bone Scintigraphy Images. Asia Ocean J Nucl Med Biol 2017;5:49-55.
28. Tamura D, Hiraga T, Myoui A, Yoshikawa H, Yoneda T. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol 2008;33:17-24.
29. Pécheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
30. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
31. Wetterwald A, van der Pluijm G, Que I, et al. Optical Imaging of Cancer Metastasis to Bone Marrow. Am J Pathol 2002;160:1143-53.
32. Bishop RT, Marino S, Carrasco G, et al. Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Lett 2020;488:27-39.
33. Bishop RT, Marino S, de Ridder D, et al. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Lett 2019;450:76-87.
34. Fathers KE, Bell ES, Rajadurai CV, et al. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res 2012;14:R74.
35. Werbeck JL, Thudi NK, Martin CK, et al. Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo. Vet Pathol 2014;51:868-81.
36. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.
37. Zhou Y, Shao G, Liu S. Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α(v)β(3)-Targeted Radiotracer( 99m)Tc-3P-RGD(2). Theranostics 2012;2:577-88.
38. Allocca G, Hughes R, Wang N, et al. The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo. J Bone Oncol 2019;17:100244.
39. Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 2017;17:302-17.
40. Holen I, Walker M, Nutter F, et al. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clin Exp Metastasis 2016;33:211-24.
41. Wang N, Reeves KJ, Brown HK, et al. The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. J Exp Clin Cancer Res 2015;34:124.
42. Ottewell PD, Wang N, Brown HK, et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 2014;20:2922-32.
43. Ottewell PD, Wang N, Brown HK, et al. OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer 2015;137:968-77.
44. Cailleau R, Young R, Olivé M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974;53:661-74.
45. Sher E, Eisman JA, Moseley JM, Martin TJ. Whole-cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47 D) in culture. Biochem J 1981;200:315-20.
46. Lv X, Dobrolecki LE, Ding Y, Rosen JM, Lewis MT, Chen X. Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer. J Vis Exp 2020;(159):10.3791/61173.
47. Fatima I, El-Ayachi I, Playa HC, et al. Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling. Cancers (Basel) 2019;11:2039.
48. Giuliano M, Herrera S, Christiny P, et al. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res 2015;17:3.
49. Pillai SG, Li S, Siddappa CM, Ellis MJ, Watson MA, Aft R. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model. Breast Cancer Res 2018;20:2.
50. Zhang W, Bado I, Wang H, Lo HC, Zhang XH. Bone Metastasis: Find Your Niche and Fit in. Trends Cancer 2019;5:95-110.
51. Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res 2005;65:6130-8.
52. Lam P, Yang W, Amemiya Y, et al. A human bone NOD/SCID mouse model to distinguish metastatic potential in primary breast cancers. Cancer Biol Ther 2009;8:1010-7.
53. Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P, Ottewell PD. Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clin Exp Metastasis 2015;32:689-702.
54. Yang W, Lam P, Kitching R, et al. Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther 2007;6:1289-94.
55. Ottewell PD, Coleman RE, Holen I. From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 2006;96:101-13.
56. Derksen PW, Braumuller TM, van der Burg E, et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 2011;4:347-58.
57. Céspedes MV, Casanova I, Parreño M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006;8:318-29.
58. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A 1995;92:3650-7.
59. Buijs JT, Matula KM, Cheung H, et al. Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase. J Pathol 2015;235:745-59.
60. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001;Chapter 20:Unit 20.2.
61. Tulotta CM, Lefley DV, Amariutei AE, et al. Inhibition of breast cancer bone metastasis through Interleukin-1B regulated tumour-associated innate immune response. Breast Cancer Res Treat 2020;180:538-9.
62. Hiraga T, Ninomiya T. Establishment and characterization of a C57BL/6 mouse model of bone metastasis of breast cancer. J Bone Miner Metab 2019;37:235-42.
63. Zhou JZ, Riquelme MA, Gao X, Ellies LG, Sun LZ, Jiang JX. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene 2015;34:1831-42.
64. Cox TC. Microcomputed tomography of craniofacial mineralized tissue: A practical user's guide to study planning and generating quality data. Bone 2020;137:115408.
65. Green AC, Lath D, Hudson K, et al. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. J Bone Miner Res 2019;34:2311-26.
66. Paton-Hough J, Tazzyman S, Evans H, et al. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. J Bone Miner Res 2019;34:783-96.
67. Westbrook JA, Cairns DA, Peng J, et al. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst 2016:108.
68. Monteran L, Ershaid N, Sabah I, et al. Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis. Sci Rep 2020;10:13838.
69. Yao L, Aryee K, Cheng M, Kaur P, Keck JG, Brehm MA. . Creation of PDX-Bearing Humanized Mice to Study Immuno-oncology. In: Moll J, Carotta S, editors. Target Identification and Validation in Drug Discovery. New York: Springer; 2019. pp. 241-52.
70. Hasgur S, Aryee KE, Shultz LD, Greiner DL, Brehm MA. . Generation of Immunodeficient Mice Bearing Human Immune Systems by the Engraftment of Hematopoietic Stem Cells. In: Proetzel G, Wiles MV, editors. Mouse Models for Drug Discovery. New York: Springer; 2016. pp. 67-78.
